Safety and Immunogenicity of GSK Meningococcal Group B Vaccine and 13-valent Pneumococcal Vaccine Administered Concomitantly With Routine Infant Vaccines to Healthy Infants

  • End date
    May 27, 2024
  • participants needed
  • sponsor
Updated on 23 October 2022
conjugate vaccine
Accepts healthy volunteers


The purpose of this study is to evaluate the safety and immunogenicity of Bexsero (meningococcal group B vaccine-rMenB+OMV NZ) in North American infants 6 weeks through 12 weeks of age, when administered concomitantly with Pneumococcal conjugate vaccine (PCV 13) and other recommended routine infant vaccines(RIV).


This study will be divided into 3 timepoints:

  • Epoch 1- Primary- From day 1 to day 301
  • Epoch 2-Secondary-From day 301 to day 331
  • Epoch 3-Safety follow up -From day 331 to study end (day 661) In addition to receiving the study vaccines, infants will also receive non-study vaccines such as Diphtheria, tetanus toxoids and acellular pertussis adsorbed vaccine (DTPa, Infanrix) and Haemophilus influenzae type b Conjugate Vaccine (Hib, Hiberix), to ease the disruption to the standard infant vaccine schedule caused by participating in this study.

Condition Infections, Meningococcal
Treatment Prevnar13, Rotarix, Bexsero (GSK Biologicals' Meningococcal group-B vaccine/ rMenB+OMV NZ), Pediarix, Hiberix, M-M-R II, Varivax, Varivax, Placebo (saline water)
Clinical Study IdentifierNCT03621670
Last Modified on23 October 2022


Yes No Not Sure

Inclusion Criteria

All subjects must satisfy all the following criteria at study entry
Subjects' parent(s)/Legally Acceptable Representative(s) [LAR(s)] who, in the opinion of the investigator, can and will comply, with the requirements of the protocol (e.g. completion of the eDiary, return for follow-up visits)
Written informed consent obtained from the parent(s)/LAR(s) of the subject prior to performing any study specific procedure
A male or female between, and including, 42 and 84 days of age (i.e., 6 through 12 weeks) at the time of the 1st vaccination
Healthy subjects as established by medical history and clinical examination before entering into the study
Born full-term (i.e. after a gestation period of ≥ 38 weeks)

Exclusion Criteria

If any exclusion criterion applies, the subject must not be included in the
• Child in care
Each subject must not have
Progressive, unstable or uncontrolled clinical conditions
Hypersensitivity, including allergy to any component of vaccines, medicinal product or medical equipment whose use is foreseen in this study
Hypersensitivity to latex
Clinical conditions representing a contraindication to intramuscular vaccination and blood draws
Abnormal function of the immune system resulting from
Clinical conditions
Systemic administration of corticosteroids (PO/IV/IM) for more than 14 consecutive days from birth
Administration of antineoplastic and immunomodulating agents or radiotherapy for any duration from birth
Autoimmune disorders (including, but not limited to: blood, endocrine, hepatic, muscular, nervous system or skin autoimmune disorders; lupus erythematosus and associated conditions; rheumatoid arthritis and associated conditions; scleroderma and associated disorders) or immunodeficiency syndromes (including, but not limited to: acquired immunodeficiency syndromes and primary immunodeficiency syndromes)
Received immunoglobulins or any blood products from birth
Received an investigational or non-registered medicinal product from birth
Any other clinical condition that, in the opinion of the investigator, might pose additional risk to the subject due to participation in the study
Neuroinflammatory disorders (including but not limited to: demyelinating disorders, encephalitis or myelitis of any origin), congenital and peripartum neurological conditions, encephalopathies, seizures (including all subtypes such as: absence seizures, generalised tonic-clonic seizures, partial complex seizures, partial simple seizures or febrile convulsions)
Congenital or peripartum disorders resulting in a chronic condition (including but not limited to: chromosomal abnormalities, cerebral palsy, metabolism or synthesis disorders, cardiac disorders)
Study personnel as an immediate family or household member
Current or previous, confirmed or suspected disease caused by N. meningitidis
Household contact with and/or intimate exposure from birth to an individual with laboratory confirmed N. meningitidis and/or Streptococcus pneumoniae infection or colonization
Previous administration of meningococcal B or pneumococcal vaccine at any time prior to informed consent
Received a dose of DTPa-HBV-IPV, HRV, MMR, VV and/or Hib at any time prior to informed consent. Receipt of one dose of HBV up to 4 weeks prior to informed con-sent is allowed
Serious chronic illness
Uncorrected congenital malformation (such as Meckel's diverticulum) of the gastrointestinal tract that would predispose for Intussusception (IS)
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note